+
Morepen Proposes Dividend After 23 Years, Logs Rs 1.18 Bn PAT in FY25
ECONOMY & POLICY

Morepen Proposes Dividend After 23 Years, Logs Rs 1.18 Bn PAT in FY25

In a landmark announcement that signals a new era of growth and financial strength, Morepen Laboratories board has proposed to declared a dividend (₹0.20 per share) after a gap of 23 years, marking a defining moment in the company’s four-decade legacy, subject to approval of the shareholders in the forthcoming Annual General Meeting.

The declaration comes on the back of excellent financial results for FY25, with gross revenue rising to Rs 18.30 billion, up from Rs 17.04 billion in FY24 — a 7.4 per cent year-on-year increase. EBITDA surged 11.5 per cent to Rs 1.92 billion, and Profit After Tax jumped to Rs 1.18 billion, while Earnings Per Share (EPS) climbed to Rs 2.20, up 17 per cent from the previous year.

Sushil Suri, Chairman & Managing Director of Morepen Laboratories, said: “This moment is symbolic – it’s not just about distributing profits; it’s about rewarding trust. We always believe in the “Joy of Growing Together”. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it’s time we give back.”

Morepen’s API business continued to dominate, contributing Rs 9.89 billion, while the Medical Devices segment surged to Rs 4.96 billion, growing 12 per cent year-on-year. With 72 per cent of API revenue coming from exports across 80+ countries, Morepen is solidifying its position as a global pharmaceutical force. Investments in new product development, capacity expansion, and global regulatory approvals continue to propel the business forward.


Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high- quality APIs, branded generics, medical devices, and consumer wellness products to over 80 countries worldwide. With an installed API capacity of 514 KL, a 14 million-strong glucometer user base, and a rapidly expanding digital footprint, Morepen stands at the forefront of India's health-tech evolution. Backed by decades of trust, regulatory approvals from USFDA, WHO, and EU bodies, and a passion for innovation, Morepen is committed to making quality healthcare accessible, affordable, and future-ready.

In a landmark announcement that signals a new era of growth and financial strength, Morepen Laboratories board has proposed to declared a dividend (₹0.20 per share) after a gap of 23 years, marking a defining moment in the company’s four-decade legacy, subject to approval of the shareholders in the forthcoming Annual General Meeting.The declaration comes on the back of excellent financial results for FY25, with gross revenue rising to Rs 18.30 billion, up from Rs 17.04 billion in FY24 — a 7.4 per cent year-on-year increase. EBITDA surged 11.5 per cent to Rs 1.92 billion, and Profit After Tax jumped to Rs 1.18 billion, while Earnings Per Share (EPS) climbed to Rs 2.20, up 17 per cent from the previous year.Sushil Suri, Chairman & Managing Director of Morepen Laboratories, said: “This moment is symbolic – it’s not just about distributing profits; it’s about rewarding trust. We always believe in the “Joy of Growing Together”. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it’s time we give back.”Morepen’s API business continued to dominate, contributing Rs 9.89 billion, while the Medical Devices segment surged to Rs 4.96 billion, growing 12 per cent year-on-year. With 72 per cent of API revenue coming from exports across 80+ countries, Morepen is solidifying its position as a global pharmaceutical force. Investments in new product development, capacity expansion, and global regulatory approvals continue to propel the business forward.Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high- quality APIs, branded generics, medical devices, and consumer wellness products to over 80 countries worldwide. With an installed API capacity of 514 KL, a 14 million-strong glucometer user base, and a rapidly expanding digital footprint, Morepen stands at the forefront of India's health-tech evolution. Backed by decades of trust, regulatory approvals from USFDA, WHO, and EU bodies, and a passion for innovation, Morepen is committed to making quality healthcare accessible, affordable, and future-ready.

Next Story
Infrastructure Urban

Naidu Seeks Rs 563 Crore For AP Sports Infrastructure

Andhra Pradesh Chief Minister N Chandrababu Naidu has sought Rs 563 crore from the Centre to boost sports infrastructure in the state, including Rs 538 crore for stadium development and Rs 25 crore to host the Khelo India Martial Arts Games 2025. Naidu made the request during a meeting with Union Youth Services and Sports Minister Mansukh Mandaviya in New Delhi on Wednesday.The CM urged early completion of Khelo India infrastructure projects in Tirupati, Rajahmundry, Kakinada, and Narasaraopeta, and called for an international-standard badminton training centre and a national aquatic sports hu..

Next Story
Infrastructure Transport

Tough Bidding Norms Slow NHAI Road Project Awards

Stringent bidding rules imposed by the Ministry of Road Transport & Highways (MoRTH) have led to a slowdown in project awards by the National Highways Authority of India (NHAI), despite a robust Rs 3.5 trillion pipeline. According to an HDFC Securities report, the shift to more cautious developer models now favours firms with strong balance sheets, as tighter qualification norms limit aggressive bidders.The revised norms mandate additional performance security, targeting the exclusion of players that previously submitted low bids—often 25 to 40 per cent below NHAI cost estimates—raisin..

Next Story
Infrastructure Transport

Mumbai Gets Coastal Nod for Next Promenade Phase

As Mumbai prepares to open two major sections of its expansive seafront promenade this week, the city’s civic authority has secured a key coastal clearance to advance further construction. The Maharashtra Coastal Zone Management Authority (MCZMA) has approved the commencement of work on the segment between Haji Ali and Baroda Palace, with tendering expected soon after project cost assessments.The promenade, stretching 7.5 km in length and 20 metres wide, is being designed as a flagship open space for walkers, joggers, and cyclists. Two critical stretches—2.75 km from Tata Garden to Haji Al..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?